Public finance fellow John Diamond analyzed the proposed Tax Reform Act of 2014 in testimony before the House Subcommittee on Select Revenue Measures on July 30, 2014.
Neal Lane, senior fellow in science and technology policy, testified before the Senate Committee on Commerce, Science and Transportation on July 17, 2014. Lane is co-chair of the American Academy of Arts and Science's project on New Models for U.S. Science and Technology Policy, and his testimony addressed the project's objective of sustaining a long-term, nonpartisan, national focus on science and technology policy issues of vital importance to the country.
Biotechnology scientists must be aware of the broad patent landscape and push for new patent and licensing guidelines, according to a new paper from the Baker Institute.
Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.
Every patient with cancer or another life-threatening disease wants the most effective treatment, but drug prices have become staggering. What determines the escalating prices of cancer drugs?
Donald Light, Hagop M. KantarjianSeptember 3, 2013
For both generic and patented cancer drugs, the free-market economy has not worked well. Solutions are needed to maintain reasonable drug prices that allow for corporate profits and are affordable to patients and to the U.S. health care system.
Hagop M. Kantarjian, Leonard A. ZwellingAugust 26, 2013
In a recent commentary, Baker Institute science and technology policy experts described two international court cases that aimed to define “research” — and that ultimately arrived at two different answers.
“What makes this interesting is that the courts’ definition of ‘research’ was based on politics — what the court wanted the end result to be,” said Kirstin Matthews, the institute’s fellow in science and technology policy. To reach a decision prohibiting human embryonic stem cell (hESC) patents, the EU court ruled that “research” occurs in a continuum. To reach a decision supporting federal funding of stem cell research, the U.S. court ruled that “research” involves a specific project.
